Back to search results

Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

HR+/HER2+ Early Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

    Contact: Study coordinator (Xiaoan Liu) · liuxiaoan@126.com · 025-83718836
    Contact: Principal Investigator (Xiaoan Liu)

  • 2nd Affiliated Hospital, School of Medicine, Hangzhou, Zhejiang, China

    Contact: Study coordinator (Yunxiang Zhou) · ydchen@zju.edu.cn · 15868131018
    Study coordinator · ydchen@zju.edu.cn
    Contact: Principal Investigator (Yiding Chen)

  • Ningbo No. 2 Hospital, Ningbo, Zhejiang, China

    Contact: Study coordinator (Wei Zhang) · 20949061@qq.com · 13586562390
    Contact: Principal Investigator (Xujun Li)
View source on ClinicalTrials.gov(opens in a new tab)